1. Mesenteric ischemia after capecitabine treatment in rectal cancer and resultant short bowel syndrome is not an absolute contraindication for radical oncological treatmentAna Perpar, Erik Brecelj, Nada Rotovnik-Kozjek, Franc Anderluh, Irena Oblak, Marija Skoblar Vidmar, Vaneja Velenik, 2015, short scientific article Abstract: Thrombotic events, arterial or venous in origin, still remain a source of substantial morbidity and mortality in cancer patients. The propensity for their development in oncology patients is partially a consequence of the disease itself and partially a result of our attempts to treat it. One of the rarest and deadliest thromboembolic complications is arterial mesenteric ischemia. The high mortality rate is caused by its rarity and by its non-specific clinical presentation, both of which make early diagnosis and treatment difficult. Hence, most diagnoses and treatments occur late in the course of the disease. The issue survivors of arterial mesenteric ischemia may face is short bowel syndrome, which has become a chronic condition after the introduction of parenteral nutrition at home. We present a 73-year-old rectal cancer patient who developed acute arterial mesenteric thrombosis at the beginning of the pre-operative radiochemotherapy. Almost the entire length of his small intestine, except for the proximal 50 cm of it, and the ascending colon had to be resected. After multiorgan failure his condition improved, and he was able to successfully complete radical treatment (preoperative radiotherapy and surgery) for the rectal carcinoma, despite developing short bowel syndrome (SBS) and being dependent upon home-based parenteral nutrition to fully cover his nutritional needs. Mesenteric ischemia and resultant short bowel syndrome are not absolute contraindications for radical oncological treatment since such patients can still achieve long-term remission.
Keywords: acute mesenteric ischemia, capecitabine, multiorgan failure, rectal cancer, short bowel syndrome
Published in DiRROS: 23.04.2024; Views: 4; Downloads: 2
 Full text (557,53 KB) |
2. Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinomaIrena Oblak, Marija Skoblar Vidmar, Franc Anderluh, Vaneja Velenik, Ana Jeromen, Jasna But-Hadžić, 2014, original scientific article Abstract: Background. In patients with non-metastatic gastric cancer surgery still remains the treatment of choice. Postoperative radiochemotherapy with 5-fluorouracil and leucovorin significantly improves the treatment outcome. The oral fluoropyrimidines, such as capecitabine, mimic continuous 5-fluorouracil infusion, are at least as effective as 5-fluorouracil, and such treatment is more comfortable for the patients. Patients and methods. In the period from October 2006 to December 2009, 101 patients with gastric cancer in stages Ib-IIIc were treated with postoperative chemoradiation with capecitabine. Distal subtotal resection of the stomach was performed in 46.3%, total resection in 50.5% and multivisceral resection in 3.2% of patients. The main endpoints of this study were loco-regional control (LRC), disease-free survival (DFS), disease-specific survival (DSS) and overall survival (OS). The rates of acute side-effects were also estimated. Results. Seventy-seven percent of patients completed the treatment according to the protocol. The median followup time of all patients was 3.9 years (range: 0.4-6.3 years) and in survivors it was 4.7 years (range: 3.2-6.3 years). No death occurred due to the therapy. Acute toxicity, such as nausea and vomiting, stomatitis, diarrhoea, hand-foot syndrome and infections of grade 3 or 4, occurred in 5%, 1%, 2%, 8.9% and 18.8% of patients, respectively. On the close-out date 63.4% patients were still alive and with no signs of the disease. The 4-years follow-up survey showed that LRC, DFS, DSS and OS were 95.5%, 69.2%, 70.7%, and 66.2%, respectively. Higher pN-stage and splenectomy were found to be independent prognostic factors for all four types of survival and perineural invasion and lower treatment intensity for DFS, DSS and OS.
Keywords: gastric cancer, adjuvant therapy, radiochemotherapy
Published in DiRROS: 11.04.2024; Views: 64; Downloads: 10
Full text (519,56 KB) |
3. Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in SloveniaAna Jeromen, Irena Oblak, Franc Anderluh, Vaneja Velenik, Marija Skoblar Vidmar, Ivica Ratoša, 2012, original scientific article Keywords: gastroesophageal junction adenocarcinoma, postoperative radiochemotherapy, toxicity
Published in DiRROS: 21.03.2024; Views: 90; Downloads: 32
Full text (419,66 KB) |
4. Tehnologija Hyper Arc za izvedbo stereotaktične radiokirurgije v zdravljenju možganskih metastazMarija Skoblar Vidmar, 2023, short scientific article Abstract: Hyper Arc je inovativna programska in strojna oprema za izvedbo stereotaktične radiokirurgije, ki je od junija 2020 dostopna na Onkološkem inštitutu Ljubljana. Omogoča visoko natančno, monoizocentrično obsevanje v teoriji neomejenega števila možganskih tarč. Najbolj uporabna je v lokalnem zdravljenju možganskih metastaz, ki so vedno pogostejši vzrok obolevnosti in umrljivosti bolnikov z malignimi boleznimi.Glede na najnovejše raziskave in smernice se stereotaktična radiokirurgija obravnava kot primarna izbira za izboljšanje preživetja in je lahko najboljša izbira zdravljenja več metastaz v možganih. Lokalna kontrola vsake obsevane lezije in morebitna pozna toksičnost sta vedno pomembnejšega kliničnega pomena, ki lahko vplivata ne le na preživetje, temveč tudi na nevrokognitivno funkcijo in kakovost življenja.
Keywords: Hyper Arc, stereotaktična radiokirurgija, možganske metastaze
Published in DiRROS: 27.07.2023; Views: 324; Downloads: 76
Full text (156,64 KB) |
5. Priporočila za obravnavo bolnikov z malignimi limfomiBarbara Jezeršek Novaković, Lučka Boltežar, Andreja Eberl, Gorana Gašljević, Biljana Grčar-Kuzmanov, Monika Jagodic, Tanja Južnič Šetina, Veronika Kloboves-Prevodnik, Gregor Kos, Aleš Christian Mihelač, Milica Miljković, Urška Rugelj, Marija Skoblar Vidmar, Uroš Smrdel, Danijela Štrbac, Miha Toplak, Lorna Zadravec-Zaletel, 2023, professional monograph Keywords: maligni limfomi, smernice, novotvorbe
Published in DiRROS: 24.01.2023; Views: 665; Downloads: 272
Full text (971,73 KB)
This document has many files! More... |
6. Stereotaktična radiokirurgija v zdravljenju tumorjev centralnega živčevjaMarija Skoblar Vidmar, 2022, published scientific conference contribution Abstract: Stereotaktična radiokirurgija (SRS) je danes priporočena metoda zdravljenja malignih in benignih
možganskih tumorjev kot tudi nevroloških funkcionalnih in vaskularnih motenj. Definirana je kot
teleradioterapijska metoda pri kateri je natančno določen tarčni volumen, ki se obseva z biološko visoko tumorsko dozo,v eni ali največ v 5 frakcijah, s strmim padcem doze na robu tarčnega volumna in z lokalno kurativnim namenom. Hyper Arc je dokaj nova in napredna tehnika monoizocentričnega SRS obsevanja multiplih tarč v kratkem času.
Keywords: možganski tumorji, centralno živčevje, radioterapija
Published in DiRROS: 16.12.2022; Views: 466; Downloads: 111
Full text (172,17 KB) |
7. Uporabnost FET PET/CT biomarkerjev pri diagnostiki ponovitve možganskih glialnih tumorjev z različnim statusom IDH mutacijMarija Skoblar Vidmar, Andrej Doma, Uroš Smrdel, Urška Zevnik, Andrej Studen, 2022, published scientific conference contribution (invited lecture) Keywords: glioblastom, obsevanje, možganski rak, možganski tumor
Published in DiRROS: 17.06.2022; Views: 520; Downloads: 177
Full text (125,57 KB) |
8. Odpornost glioblastoma na radioterapijo : vpliv rakavih matičnih celic in mikroo[ko]lja tumorjaBarbara Breznik, Bernarda Majc, Anamarija Habič, Urška Ušeničnik, Andrej Porčnik, Roman Bošnjak, Jernej Mlakar, Marija Skoblar Vidmar, Tanja Jesenko, Maja Čemažar, Tamara Lah Turnšek, Metka Novak, 2022, published scientific conference contribution (invited lecture) Abstract: Glioblastom je najpogostejši možganski tumor pri odraslih z zelo slabo prognozo preživetja bolnikov. Ta je posledica odpornosti glioblastoma na standardno zdravljenje, ki vključuje radioterapijo in kemoterapijo. Z namenom načrtovanja učinkovitejših pristopov zdravljenja preučujemo biološke mehanizme odpornosti glioblastoma na radioterapijo s poudarkom na mikrookolju tumorja in rakavih matičnih celicah. V predkliničnih raziskavah uporabljamo napredne in personalizirane celične modele, ki posnemajo mikrookolje tumorja v bolnikih in z večjo natančnostjo napovedo odziv bolnika na zdravljenje. Hkrati so takšni modeli pomembni za testiranje novih pristopov za zdravljenje kot je imunoterapija.
Keywords: glioblastom, mikrookolje, organoidi, možganski rak, možganski tumor, onkologija
Published in DiRROS: 16.06.2022; Views: 596; Downloads: 194
Full text (89,78 KB) |
9. |
10. Minimalno invazivni diagnostični pristopi pri primarnih možganskih tumorjih z uporabo prosto cirkulirajočih nukleinskih kislinMarija Skoblar Vidmar, Jernej Mlakar, Uroš Smrdel, Alenka Matjašič, Jože Pižem, Andrej Zupan, 2021, published scientific conference contribution Keywords: tekočinska biopsija, onkološko zdravljenje, možganski tumorji
Published in DiRROS: 04.04.2022; Views: 582; Downloads: 225
Full text (123,97 KB) |
